Compare RNA & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | FT |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.5M | 199.8M |
| IPO Year | 2025 | N/A |
| Metric | RNA | FT |
|---|---|---|
| Price | $12.83 | $8.22 |
| Analyst Decision | Buy | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $69.26 | N/A |
| AVG Volume (30 Days) | ★ 340.0K | 31.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $7.37 |
| 52 Week High | $73.06 | $8.35 |
| Indicator | RNA | FT |
|---|---|---|
| Relative Strength Index (RSI) | 28.53 | 52.95 |
| Support Level | $11.95 | $7.80 |
| Resistance Level | $14.80 | $8.24 |
| Average True Range (ATR) | 0.65 | 0.09 |
| MACD | 0.73 | -0.01 |
| Stochastic Oscillator | 15.09 | 42.31 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.